HEPATOCELLULAR CARCINOMA (HCC)

This study tests a DNA vaccine called NWRD06 in 30 adults with a type of liver cancer (hepatocellular carcinoma) that has been surgically removed. The vaccine targets a protein called GPC3 found on cancer cells, aiming to train the immune system to destroy any remaining cancer an…

This study tests if a newer type of chemoembolization (DEB-TACE) works better and is safer than the standard version (cTACE) for people with liver cancer that has spread beyond the Milan criteria and who have had a TIPS procedure to manage complications of cirrhosis. About 206 pa…

This study tests whether combining two drugs (sintilimab and bevacizumab) after surgery can prevent liver cancer from coming back in patients whose tumor ruptured. About 35 adults with this high-risk condition will receive the treatment. The goal is to see if this approach is saf…

This study tests whether adding Icaritin soft capsules to standard liver artery chemotherapy (HAIC) can help prevent liver cancer from returning after surgery. It involves 30 adults with high-risk liver cancer who have recently had their tumor removed. The goal is to see if this …

This early-stage study tests a new drug called XL092, alone or with other immune-boosting drugs, in people with advanced solid tumors (like kidney, prostate, lung, or colon cancer) that can't be removed by surgery. The main goals are to find safe doses and see if the treatment sh…

This early-phase study tests a new drug called Sapu003 in 27 adults with advanced solid tumors (like breast, kidney, or liver cancer) that are sensitive to mTOR-targeted therapy. The main goal is to find the safest dose and check for side effects. Participants receive Sapu003 wee…

This study is for people with advanced liver cancer whose disease got worse after initial treatment with atezolizumab and bevacizumab. Researchers want to see if adding a chemotherapy regimen called FOLFOX to the same two drugs can help shrink tumors or slow the cancer. About 30 …

This study tests a personalized mRNA vaccine (iNeo-Vac-R01) made from a patient's own tumor, given together with an immunotherapy drug (PD-1 inhibitor) after liver cancer surgery. The goal is to train the immune system to kill any remaining cancer cells and prevent the cancer fro…

This early-phase study tests a new drug called CTX-10726 in people with advanced cancers (stomach, liver, uterine, or kidney) that have not responded to standard treatments. The main goal is to check the drug's safety and find the best dose. About 70 adults will take part, and th…

This early-stage study tests a new drug called CREPT-618 in about 13 adults with advanced liver cancer that has not responded to standard treatments. The main goal is to check the drug's safety and find the best dose. Researchers will also look at how the drug moves through the b…

This study tests whether giving a drug called polyene phosphatidylcholine before and after laparoscopic liver surgery can reduce liver damage in people with liver cancer. About 96 adults will be split into two groups: one gets the drug combo, the other gets standard care. The mai…

This study tests a new approach for people with advanced liver cancer that cannot be removed with surgery. Participants receive a sequence of treatments: chemotherapy directly into the liver, two drugs (durvalumab and bevacizumab) that boost the immune system and block blood vess…

This study tests whether giving a combination of two drugs (apatinib and camrelizumab) along with a procedure called TACE before liver surgery can shrink tumors and lower the chance of cancer coming back. It includes 27 adults with a specific type of liver cancer that can be remo…

This study tests a new drug called ABSK-011 for people with advanced liver cancer that has not responded to previous treatments. The drug targets a specific protein (FGF19) found in some tumors. About 141 participants will receive either ABSK-011 or a placebo, both with standard …

This study tests a combination of two drugs—tislelizumab (an immunotherapy) and huaier granule (a traditional Chinese medicine)—as the first treatment for people with liver cancer that cannot be removed by surgery. About 94 adults with advanced liver cancer will receive this comb…

This study is testing whether a radiation treatment for large liver tumors (over 5 cm) can be safely done in a single day. Normally, this treatment requires multiple visits. The researchers will enroll 138 patients with liver cancer who meet specific health criteria. The goal is …

This study tests a new drug called pumitamig, either alone or with another drug (ipilimumab), in people with advanced liver cancer that cannot be removed by surgery. About 129 participants will receive the treatment to see if it is safe and helps shrink tumors. The goal is to con…

This study tests two different radiation methods (SBRT and SIRT) given with immunotherapy for people with advanced liver cancer that cannot be surgically removed. About 106 participants will be randomly assigned to one of the two treatments. The goal is to see which approach bett…

This study tests whether a treatment called TACE (a procedure that blocks blood flow to the tumor) combined with the drug icaritin can help prevent liver cancer from returning after surgery. It includes 30 adults with hepatocellular carcinoma who are at high risk of recurrence. T…

This study tests a combination of two drugs, IBI310 and sintilimab, as a first treatment for people with advanced liver cancer that cannot be removed by surgery. About 680 participants will receive the combo to see if it shrinks tumors and helps them live longer. The goal is to c…

This study tests whether adding a liver-directed chemotherapy (HAIC) to a combination of two drugs (sintilimab and bevacizumab) can help people with advanced liver cancer live longer without the disease getting worse. About 164 adults who have not had prior systemic therapy will …

This study is for people with advanced liver cancer who are starting a combination of two drugs (atezolizumab and bevacizumab). It tests whether adding a procedure called TIPS (which creates a small channel in the liver to reduce pressure) can help keep the liver working longer. …

This study looks at whether giving chemotherapy directly into the liver artery after surgery can help prevent liver cancer from coming back in people at high risk. About 30 adults who had their liver cancer removed will receive this treatment. The goal is to see if it improves ho…

This study tests a pair of drugs: one that lights up cancer cells on scans (RYZ811) and another that delivers radiation directly to those cells (RYZ801). It is for adults with a type of liver cancer (GPC3-positive) that cannot be removed by surgery and has worsened after one prio…

This early-phase trial tests an experimental oral drug called ST-01156 in about 171 adults with advanced solid tumors, including Ewing sarcoma, liver cancer, and bile duct cancer. The drug works by breaking down a protein inside cancer cells. The main goals are to find a safe dos…

This study compares a new biosimilar drug (HLX13) to the standard drug YERVOY® for people with advanced liver cancer that cannot be removed by surgery. About 246 adults aged 18-65 will receive either the new drug or the standard one. The goal is to see if the new drug works just …

This study tests whether combining radiation with an immunotherapy drug (sintilimab) works better than a standard procedure (TACE) to keep liver cancer from returning after surgery. It includes 286 adults whose tumors were removed but had narrow margins and high-risk features. Th…

This study tests whether a computer guidance software can help doctors more completely destroy liver tumors during a microwave ablation procedure. About 84 adults with liver cancer will have the software-assisted treatment and be followed for two years. The goal is to see if the …

This study tests a combination of two experimental drugs (AK104/AK112 and TT-00420) in 100 adults with advanced liver cancer that cannot be treated with surgery. The goal is to see if the drugs can shrink tumors and control the disease. Participants must not have had prior cancer…

This study tests a new approach for people with borderline resectable liver cancer, especially Native Hawaiian and Pacific Islander communities who are often hit harder by this disease. Participants will receive two immunotherapy drugs (ipilimumab and nivolumab) plus targeted rad…

This study tests a faster, simpler way to treat small liver cancers (up to 5 cm) using tiny radioactive beads. Normally, doctors do a special scan first to check where the beads go, but this study skips that step for certain patients. The goal is to see if the new approach is sti…

This study tests a new combination treatment for people with advanced liver cancer that cannot be removed by surgery. It combines a procedure that blocks the tumor's blood supply (TACE) with three immunotherapy drugs (sintilimab, bevacizumab, and ipilimumab). The goal is to see i…

This early-phase study tests a new drug called CBA-1205, an antibody that targets a protein (DLK1) found on some cancer cells. The main goal is to check safety and find the right dose in about 66 adults with advanced solid tumors, including liver cancer and melanoma. Participants…

This study is developing a computer system that uses CT scans and artificial intelligence to predict whether liver cancer has started to invade nearby blood vessels, a condition called microvascular invasion. Currently, this can only be confirmed after surgery by examining remove…

This study is testing a new imaging agent called 18F-T2, which targets a protein (CAIX) found on many solid tumors. About 200 adults with cancers like kidney, bladder, colorectal, or lung cancer will receive a PET/CT scan using this agent. The goal is to see if it can find tumors…

This study tests a new way of doing PET scans that uses two different tracers at the same time to get a more complete picture of liver and pancreatic tumors. Researchers want to see if this "multiplexed" method finds more tumors and gives clearer information than the standard sin…

This study is testing a new radioactive tracer called 89Zr-TLX250 to see if it can better detect liver cancers (hepatocellular carcinoma and intrahepatic cholangiocarcinoma) and pancreatic neuroendocrine tumors on PET-CT scans. About 60 adults with these cancers will receive the …

This study aims to create a blood test that can detect several types of gastrointestinal cancers—like liver, pancreatic, and colon cancer—at an early stage. Current screening methods are often invasive or not sensitive enough. The test looks for tiny molecules called miRNAs in th…

This study aims to develop a blood test that can detect liver cancer (hepatocellular carcinoma) at an early stage, when treatment is more likely to work. Researchers will analyze tiny genetic molecules in the blood of 600 people already diagnosed with liver cancer to see if they …

This study is testing whether offering liver cancer screening every 6 months to people with cirrhosis can reduce deaths from liver cancer. About 617 participants in one region of Denmark will get an ultrasound and blood test. Their outcomes will be compared to similar patients in…

This study tests whether a smartphone app that lets liver cancer patients regularly report their symptoms can improve their quality of life during immunotherapy. 500 adults with liver cancer will either use the app to get personalized advice and alerts or receive standard care. T…

This study looks at whether a patient's emotional state—like depression or anxiety—can influence how well advanced liver cancer responds to a combination of chemotherapy, targeted therapy, and immunotherapy. Researchers will follow 90 adults with BCLC stage B or C liver cancer, d…

This study is testing whether a blood test (liquid biopsy) can predict how well liver cancer responds to a targeted radiation treatment called Y90 radioembolization. Researchers will take blood samples from 12 adults with liver cancer before and after treatment to look for cancer…

This study is looking at whether certain substances in the blood can help doctors predict how well a liver cancer treatment called TACE is working. About 15 adults with liver cancer who are scheduled for TACE will give blood samples before and after treatment. The goal is to see …

This study involves 30 adults with liver tumors who are scheduled for radioembolization, a treatment that delivers radiation directly to the tumor via tiny beads. Doctors currently use a test with a different particle (MAA) to see if the treatment might harm the lungs, but this t…

This study is looking at 600 adults with liver cirrhosis to see which imaging method—MRI or ultrasound—works better for finding liver cancer early. Researchers will also track body composition and other health changes over time. The goal is to improve how doctors monitor and pred…

This study aims to make a common liver cancer treatment called TARE more predictable and effective. Researchers will create computer models of each patient's liver blood vessels to simulate how radioactive beads spread during treatment. By analyzing factors like catheter position…

This study tests whether an artificial intelligence (AI) tool can help doctors more accurately stage and plan treatment for liver cancer (hepatocellular carcinoma). About 108 patients and their doctors will participate, with some doctors using the AI tool and others not. The goal…